Cardiovascular outcomes trials with GLP-1 receptor agonists
Cardiovascular outcomes trials with GLP-1 receptor agonists
This module summarises reported and ongoing GLP-1 receptor agonist CVOTs including lixisenatide (ELIXA), liraglutide (LEADER), semaglutide (SUSTAIN-6) and exenatide (EXSCEL).
Cardiovascular outcomes trials with GLP-1 receptor agonists
Timeline of new treatment options
CVOTs are being conducted for compounds within the newer classes of glucose-lowering agents in patients with T2D
CVOTs are being conducted for compounds within the GLP-1 receptor agonist class in patients with T2D
GLP-1 receptor agonists have pharmacological differences
Summary of completed GLP-1 receptor agonist CVOTs
Baseline characteristics in completed GLP‑1 receptor agonist CVOTs
Baseline CV disease in completed GLP‑1 receptor agonist CVOTs
Baseline kidney function in completed GLP‑1 receptor agonist CVOTs
Baseline medications in completed GLP‑1 receptor agonist CVOTs
ELIXA: study design
LEADER: study design
SUSTAIN-6: study design
FREEDOM-CVO: study design
EXSCEL: study design
Harmony Outcomes: study design
REWIND: study design
PIONEER 6: study design
MACE in completed GLP-1 receptor agonist CVOTs in patients with T2D
CV death in completed GLP-1 receptor agonist CVOTs in patients with T2D
Stroke in completed GLP-1 receptor agonist CVOTs in patients with T2D
MI in completed GLP-1 receptor agonist CVOTs in patients with T2D
All-cause mortality in completed GLP-1 receptor agonist CVOTs in patients with T2D
HHF in completed GLP-1 receptor agonist CVOTs in patients with T2D
Kidney outcomes in patients with T2D: LEADER and SUSTAIN-6
Kidney outcomes in patients with T2D: REWIND
Retinopathy outcomes in completed GLP-1 receptor agonist CVOTs in patients with T2D
Overview of selected AEs from completed GLP-1 receptor agonist CVOTs in patients with T2D
GLP-1 receptor agonist CVOTs: summary
Back-up slides
MACE outcomes in completed SGLT2 inhibitor and GLP-1 receptor agonist CVOTs in patients with T2D
HHF outcomes in completed SGLT2 inhibitor and GLP-1 receptor agonist CVOTs in patients with T2D
CV death outcomes in completed SGLT2 inhibitor and GLP‑1 receptor agonist CVOTs in patients with T2D
Composite kidney outcomes in SGLT2 inhibitor and GLP-1 receptor agonist CVOTs and cardiorenal trials in patients with T2D
Hard kidney outcomes in SGLT2 inhibitor, GLP-1 receptor agonist and DPP-4 inhibitor CVOTs and cardiorenal trials in patients with T2D
Hard kidney outcomes and albuminuria in completed CV, cardiorenal and HF trials in patients with T2D
Evidence from CVOTs has shown that some glucose-lowering therapies have beneficial effects on CV outcomes
Overview of CV outcomes from GLP-1 receptor agonist CVOTs in patients with T2D (1/4)
Overview of CV outcomes from GLP-1 receptor agonist CVOTs in patients with T2D (2/4)
Overview of CV outcomes from GLP-1 receptor agonist CVOTs in patients with T2D (3/4)
Overview of CV outcomes from GLP-1 receptor agonist CVOTs in patients with T2D (4/4)
Overview of selected AEs from completed GLP-1 receptor agonist CVOTs in patients with T2D
Rate this content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content